Related Experiment Videos

Endopeptidase 24.11/CD10 is down-regulated in renal cell cancer

B Göhring1, H J Holzhausen, A Meye

  • 1Department of Urology, Martin-Luther-University Halle-Wittenberg, Halle, Germany.

Insights

Renal cell cancer (RCC) shows altered expression of key membrane peptidases. Neutral endopeptidase 24.11 (NEP) is downregulated in clear cell RCC, impacting cancer progression.

Area of Science:

  • Nephrology
  • Oncology
  • Biochemistry

Background:

  • Malignant transformation in renal cell cancer (RCC) involves unclear regulatory mechanisms.
  • Biologically active peptides may influence RCC behavior, modulated by tumor cell surface enzymes.

Purpose of the Study:

  • To investigate the expression of membrane peptidases in RCC.
  • To understand the role of these enzymes in RCC pathogenesis and progression.

Main Methods:

  • Immunohistochemistry and enzyme-histochemistry were used.
  • Examined membrane peptidase expression in 44 RCC samples and adjacent renal parenchyma.

Main Results:

  • Neutral endopeptidase 24.11 (NEP) protein expression and activity were significantly downregulated in clear cell/chromophilic RCC.
  • Dipeptidyl peptidase IV (DPIV) showed strong expression, decreased only in chromophobe RCC.
  • Aminopeptidase N (APN) and Aminopeptidase A (APA) expression was attenuated in some clear cell RCC.
  • Chromophobe RCC and oncocytomas lacked expression of APN, APA, NEP, and gamma-glutamyltranspeptidase.

Conclusions:

  • Specific membrane peptidases, particularly NEP, exhibit altered expression patterns in different RCC subtypes.
  • These peptidase alterations may play a role in RCC development and progression.
  • Findings suggest potential diagnostic or therapeutic targets based on peptidase profiles.

Related Concept Videos